ESMO LBA Insights | The ADC Moment in Gynecologic Oncology: Professor Domenica Lorusso Discusses the TroFuse-005 Study

ESMO LBA Insights | The ADC Moment in Gynecologic Oncology: Professor Domenica Lorusso Discusses the TroFuse-005 Study

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. In the field of gynecologic oncology, one major study that attracted considerable attention was expected to reshape the treatment landscape for advanced endometrial cancer in the later-line setting. The randomized, open-label, global phase III TroFuse-005 study (ENGOT-en23/GOG-3095) demonstrated that the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (Sac-TMT) significantly improved progression-free survival (PFS) and overall survival (OS) compared with treatment of physician's choice (TPC) in patients with previously treated advanced or recurrent endometrial cancer. The objective response rate (ORR) was nearly doubled, making Sac-TMT the first TROP2 ADC in this patient population to demonstrate improvements in both OS and PFS compared with chemotherapy.
Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

At the 2026 European Society for Medical Oncology (ESMO) Congress, the Department of Urology at West China Hospital of Sichuan University reported interim results from the WUTSUP-02 study, which explored the value of neoadjuvant treatment with disitamab vedotin plus tislelizumab, followed by surgery and adjuvant tislelizumab, in patients with high-risk upper tract urothelial carcinoma (UTUC). Addressing the limited perioperative treatment options for this patient population, Professor Yige Bao of West China Hospital of Sichuan University discusses the rationale behind the WUTSUP-02 study, its interim efficacy findings, and future directions for patient selection and evidence generation.
ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

RET fusions are rare oncogenic driver alterations in NSCLC. As the first RET inhibitor approved in China, pralsetinib has the ARROW study as a key foundation of its clinical evidence. A post hoc reanalysis presented at ESMO 2026 showed that first-line pralsetinib provides significant benefits in tumor shrinkage and disease control, while also improving tumor-related symptoms and supporting both efficacy and quality of life. Oncology Frontier invited Professor Yilong Wu from Guangdong Provincial People's Hospital to interpret the findings. He emphasized that results from single-arm studies should not be directly compared across trials and that baseline imbalances must be taken into account. These findings provide important evidence supporting first-line treatment of advanced RET fusion-positive NSCLC.
ESMO Expert Roundtable | First Global Phase III Success for TroFuse-005: Sacituzumab Tirumotecan Establishes a New Standard of Care for Previously Treated Advanced Endometrial Cancer

ESMO Expert Roundtable | First Global Phase III Success for TroFuse-005: Sacituzumab Tirumotecan Establishes a New Standard of Care for Previously Treated Advanced Endometrial Cancer

For a long time, patients with recurrent or metastatic endometrial cancer whose disease progresses after immunotherapy have had extremely limited benefit from chemotherapy, leaving them with few effective options in later lines of treatment. At the 2026 ESMO Congress, the Phase III TroFuse-005 study, presented as a late-breaking abstract (LBA), demonstrated that sacituzumab tirumotecan (Sac-TMT), a China-developed TROP2-targeted antibody-drug conjugate (ADC), significantly improved progression-free survival (PFS) and overall survival (OS) in this patient population.
ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

Recurrent high-grade glioma (HGG) is associated with an extremely poor prognosis, particularly in patients with IDH-wildtype disease, whose median overall survival (OS) is only 6–10 months. Although targeted therapies have made progress, treatment of central nervous system (CNS) tumors remains extremely challenging because of the physiological barrier posed by the blood–brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, the team led by Professor Wenbin Li, Head of the Department of Neuro-Oncology at Beijing GoBroad Hospital, presented two research findings: an oral presentation of phase I data on the novel BRAF inhibitor HSK42360 in recurrent glioma, and large-scale prospective multicenter data on teniposide combined with platinum-based chemotherapy for recurrent HGG. On October 31, the 6th iHope Innovation Medicine Forum was held, focusing on the development of an Academic Research Organization (ARO) clinical research system and showcasing GoBroad Hospital's capabilities in building international multicenter clinical research networks and translating cutting-edge technologies into clinical practice. In this article, Professor Wenbin Li discusses breakthroughs in the clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.
Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

During the 2026 European Society for Medical Oncology (ESMO) Congress, first-line treatment options for patients with favorable-risk advanced renal cell carcinoma (RCC) attracted considerable attention. For this patient population, how to control disease while reducing the burden of long-term treatment remains an important question warranting further investigation. Oncology Frontier – UroStream invited Professor Jun Guo of Peking University Cancer Hospital to discuss the patient selection, dual-target blockade strategy, and potential clinical value of ivonescimab.
ESMO 2026 | Oligometastatic Cervical Cancer Study Reports Promising Results: QL1706 Plus Chemotherapy Followed by Definitive Radiotherapy Achieves an ORR of 90.91%

ESMO 2026 | Oligometastatic Cervical Cancer Study Reports Promising Results: QL1706 Plus Chemotherapy Followed by Definitive Radiotherapy Achieves an ORR of 90.91%

Patients with oligometastatic cervical cancer face a risk of systemic recurrence but may also benefit from aggressive local treatment. During ESMO 2026, results were reported from a Chinese single-arm Phase II study evaluating QL1706 plus chemotherapy, followed by definitive radiotherapy and continued immunotherapy maintenance. A total of 28 patients were enrolled. Among the 22 evaluable patients, the objective response rate (ORR) was 90.91%, and the disease control rate (DCR) was 100%. After a median follow-up of 8.25 months, median progression-free survival (PFS) had not yet been reached. Oncology Frontier invited Professor Peng Xie from Shandong Cancer Hospital and Institute, affiliated with Shandong First Medical University, to discuss the study design, efficacy findings, and safety management, and to share his perspectives on clinical practice.
ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

In the treatment of head and neck cancers, particularly oral squamous cell carcinoma (OSCC), clinicians have long faced a difficult trade-off: achieving radical tumor control often requires surgery that sacrifices critical anatomical structures, including the tongue, floor of the mouth, and jawbone, all of which are essential for speech, swallowing, and appearance. To further reduce the risk of local recurrence, postoperative radiotherapy or concurrent chemoradiotherapy is frequently added. However, the resulting complications, such as trismus, xerostomia, dysphagia, and tissue fibrosis, can continue to impair patients' quality of life for years.
ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. During the Head and Neck Cancer Oral Presentation Session, the Phase II results of the HexAgon-HN study (LBA42) were presented. The study evaluated the efficacy and safety of the hexavalent OX40 agonist INBRX-106 plus pembrolizumab (P) versus pembrolizumab monotherapy as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with a PD-L1 combined positive score (CPS) ≥20. The results showed that the objective response rate (ORR) in the combination group reached 48.3%, representing an absolute improvement of 21.8 percentage points over the monotherapy group (26.5%). The benefit was particularly pronounced in the HPV-positive subgroup (80.0% vs. 33.3%). This also represents the first positive proof-of-concept result from a randomized controlled trial of an OX40 costimulatory pathway agonist in cancer immunotherapy.
ESMO China Voice | Professor Li Wenbin: Breaking the Blood-Brain Barrier — Novel Targeted and Chemotherapy Regimens Bring a Survival Breakthrough for Recurrent Glioma

ESMO China Voice | Professor Li Wenbin: Breaking the Blood-Brain Barrier — Novel Targeted and Chemotherapy Regimens Bring a Survival Breakthrough for Recurrent Glioma

Recurrent high-grade glioma (HGG) has an extremely poor prognosis, particularly in IDH-wildtype patients, with a median overall survival (OS) of only 6–10 months. Despite progress in targeted therapy, the treatment of central nervous system (CNS) tumors remains a significant challenge due to the physiological barrier of the blood-brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Wenbin Li’s team from the Comprehensive Neuro-Oncology Center, Beijing GoBroad Hospital, presented two research findings: a Phase I oral presentation on the novel BRAF inhibitor HSK42360 in recurrent glioma, and multicenter, large-sample prospective data on teniposide combined with platinum for recurrent HGG. On October 31, the 6th iHope Innovative Medicine Forum was held. With the construction of the ARO (Academic Research Organization) clinical research system as its core, the forum demonstrated Beijing GoBroad Hospital’s strength in building a multinational, multicenter clinical research system and translating cutting-edge technologies. Oncology Frontier invited Professor Li Wenbin to interpret the breakthroughs in clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.